covid impact compani reaffirm clinic
messag report financi result pipelin updat
within investor expect compani re-affirmed clinic mileston
guidanc complet enrol phase intrigu trial provid multipl readout
earlier pipelin agent rebastinib inhibitor inhibitor
submit ind autophagi ulk inhibitor
updat estim maintain buy rate
compani reiter time near-term clinic mileston modest impact
pandem highlight relat chang includ
slowdown paus patient enrol select clinic trial site particularli
inhibitor tenosynovi giant cell tumor tgct given lethal
malign prepar virtual market ahead ripretinib potenti approv
gist pdufa date
commerci prepar underway adapt launch post-
covid environ compani team sale rep extens
oral oncolog launch experi despit dramat decreas in-person sale
interact oncologist increasingli open virtual interact accord management
note patient visit decreas compar pre-covid level
overal impact oncolog less sever rel indic said compani
believ impact might affect initi rate ripretinib uptak post-
launch like increas util patient assist program
expect enrol patient on-going phase intrigu studi
gist current site countri recal intrigu
origin design random patient ripretinib activ compar
sutent compani previous disclos upsiz trial due higher-
than-expect rate patient censor driven sever factor includ discontinu
local progress without central confirm withdraw consent patient never
receiv therapi random link said statist power assumpt
remain trial remain on-track complet enrol
inhibitor rebastinib data endometri cancer abstract
also see planner increment posit news includ
advanc rebastinib paclitaxel stage on-going simon two-stag studi
endometri ovarian cancer cohort cohort achiev respons
least orr expand enrol patient compani also initi
carcinosarcoma cohort paclitaxel combin trial continu enrol patient
phase ib/ii trial combin carboplatin
rest pipelin on-track despit slowdown enrol
inhibitor tenosynovi giant cell tumor patient remain on-track read
updat data select go-forward autophagi ulk kinas inhibitor
also remain on-track potenti ind submiss
updat model account result maintain buy pt
end quarter cash invest compani expect
provid runway modestli increas near-term oper
expens forecast account result also modestli reduc near-
term revenu forecast assum revenu
respect vs consensu respect
page analyst certif import disclosur
valuat risk
price target per share base probability-adjust estim gist net cash balanc
sheet year use discount cash flow analysi use wacc termin growth rate appli
termin year post-assum gener entri
risk rate valuat includ regulatori commerci setback potenti emerg new
competitor lower product sale expect cash flow-neg compani may also engag financ activ
dilut exist sharehold
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
